## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/525,113	02/18/2005	Francis J. Carr	MER-138	2814
2387 7590 06/29/2007 OLSON & HIERL, LTD. 20 NORTH WACKER DRIVE 36TH FLOOR CHICAGO, IL 60606			EXAMINER	
			HINES, JANA A	
			ART UNIT	PAPER NUMBER
			1645	
•				
		•	MAIL DATE	DELIVERY MODE
			06/29/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

·	Application No.	Applicant(s)			
	10/525,113	CARR ET AL			
Office Action Summary	Examiner	Art Unit			
	Ja-Na Hines	1645			
The MAILING DATE of this communication app Period for Reply	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period way realize to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 6(a). In no event, however, may a reply be tim fill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONE	l. ely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 18 Fe	ebruary 2005.				
2a) This action is <b>FINAL</b> . 2b) This	This action is <b>FINAL</b> . 2b) This action is non-final.				
3) Since this application is in condition for allowar	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4)⊠ Claim(s) <u>1 and 17-37</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) 1 and 17-37 are subject to restriction and/or election requirement.					
Application Papers					
9) The specification is objected to by the Examiner	·.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
·					
Attachment(s)  1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)			
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te			
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Dother:				

Application/Control Number: 10/525,113

Art Unit: 1645

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

2. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, drawn to a modified molecule wherein the selected T-cell epitopes to be removed are located on a SINGLE string termed R1 to R3 is selected.

Group II, claim(s) 17-20, 30, 33 and 34, drawn to an isolated polypeptide wherein a SINGLE epitope region is selected from: R1 and includes claim 18; R2 and includes claim 19; and R3 and includes claim 20.

Group III, claim(s) 21-26 and 31, drawn to a an isolated polypeptide including at least one amino acid residue substitution in a SINGLE epitope region selected from the group consisting of R1a and claim 22; Rib and claim 23; R1c and claim 24; R2a and claim 25; and R3a and claim 26.

Group IV, claim(s) 27, 32, and 35-36, drawn to an isolated polypeptide.

Group V, claim(s) 28, drawn to an isolated nucleic acid sequence.

Group VI, claim(s) 29, drawn to an isolated nucleic acid sequence.

3. Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Application/Control Number: 10/525,113 Page 3

Art Unit: 1645

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 4. The claims are deemed to correspond to the species listed above in the following manner: The following claim(s) are generic: 1, 17-37.
- 5. The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:
- 6. Inventions I-VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects. In the instant case the different product inventions are: Group I is drawn to a modified molecule; Group II is drawn to an isolated polypeptide; Group III is drawn to another isolated polypeptide; Groups V and IV are drawn to isolated nucleic acid sequences. Each product has a different special technical feature, i.e., the polypeptides have the different characteristics and different epitope regions unlike the other groups. The polypeptides and nucleotide sequences of groups V and VI are structurally different and have different functions which allow for different technical features. Accordingly, the groups lack the same technical feature.

Application/Control Number: 10/525,113

Art Unit: 1645

7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ja-Na Hines whose telephone number is 571-272-0859. The examiner can normally be reached on Monday-Thursday and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Jeffery Siew, can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/525,113

**Art Unit: 1645** 

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ja-Na Hines

June 22, 2007

MARK NAVARRO PRIMARY EXAMINER